AstraZeneca earnings q3 2018


“Every single new product we’ve launched is doing very well,” he added. Shares of the company were up 1.8 percent on Thursday morning.

Total revenue, however, fell 14 percent in dollar terms to $5.34 billion and core earnings per share, which exclude some items, were down 37 percent to 71 cents, reflecting lower income from divestments and investment behind new drug launches.

Analysts, on average, had forecast earnings of 72 cents on revenue of $5.30 billion, Refinitiv data showed. For the full year, the company kept its financial guidance unchanged.

Source link

Products You May Like

Articles You May Like

Facebook ‘has created too many adversaries’: Stifel lowers to ‘hold’
All the space department stores take up could build 350 malls
Dollar General cuts full-year forecast on higher costs, shares fall 
Treasury yields slide amid safe haven buying, curve inversion worries
Year-end portfolio moves to make even with this week’s market rout

Leave a Reply

Your email address will not be published. Required fields are marked *